Moderna, Inc.

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2026-03-06 EST			5-day change	1st Jan Change
52.52 ^USD	-2.43%		-1.96%	+78.09%

03-05	Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating	MT
03-04	US stocks close up on Iran diplomacy hopes; tech leads rebound	RE

Wall Street gains muted after strong jobs data nibbles at Fed rate cut bets

Published on 02/11/2026 at 04:05 pm EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Moderna, Inc.

03-05	Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating	MT
03-04	US stocks close up on Iran diplomacy hopes; tech leads rebound	RE
03-04	Health Care Up, But not by Much, on Cyclical Bias - Health Care Roundup	DJ
03-04	Equities Rise on Upbeat Data as Markets Look Past Middle East Conflict	MT
03-04	US Equity Markets End Higher After Strong Services, Jobs Data	MT
03-04	Moderna Shares Rise After Company Enters Settlement Agreement with Arbutus Biopharma, Genevant Sciences	MT
03-04	Equities Rise Intraday as Markets Parse Macro Data Amid Middle East Conflict	MT
03-04	US stocks close up on Iran diplomacy hopes; tech leads rebound	RE
03-04	Wall Street mixed as oil retreat eases inflation fears
03-04	Top Midday Stories: Bessent Says US to Fortify Gulf Oil Trade, 15% Tariff Rolling Out This Week; CrowdStrike Fiscal Q4 Adjusted Earnings, Revenue Increase	MT
03-04	Moderna rises on $2.25 billion settlement, clearing COVID vaccine patent dispute overhang	RE
03-04	Global markets live: Goldman Sachs, Meta, Intel, Moderna, Adidas…
03-04	Moderna to pay $950m to end litigation
03-04	Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang	RE
03-03	Moderna Enters Settlement Agreement with Arbutus Biopharma, Genevant Sciences	MT

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).

Employees

4,700

Sector

Pharmaceuticals

More about the company